UNSPSC 51314358: Clemastine/phenylpropanolamine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE501. This VA Drug Class (RE501) classifies this compound as belonging to the group ANTIHISTAMINE/DECONGESTANT.

UNSPSC 51314358 Clemastine/phenylpropanolamine is a Commodity code that covers antihistamine and decongestant pharmaceutical products; however, recent state and local solicitations tagged under this code show minimal activity directly aligned with its nominal scope. Instead, the few posted opportunities focus on broader pharmaceutical procurement categories—naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products, and direct-to-manufacturer prescription programs—that fall outside the specific active-ingredient focus of the code itself. State and local issuing bodies pursuing pharmaceutical supply under related codes include county health departments (Seminole County, Florida), state human services commissions (Texas HHS Commission), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). The code shows little decision-relevant recent activity directly tied to clemastine or phenylpropanolamine products; procurement in this therapeutic space appears to be captured under broader pharmaceutical sourcing efforts rather than at the ingredient-specific commodity level.

Geographic activity supporting the broader pharmaceutical-supply codes spans Florida, Texas, Minnesota, and Oregon, with cooperative purchasing vehicles amplifying reach across state lines. Representative recent opportunities include Seminole County's IFB 60459723LAS (posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries, MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (posted January 20, 2026, due March 26, 2026) serving participating state and local facilities across multiple jurisdictions with awards effective July 1, 2026, and the Texas HHS Commission's Request for Information HHS0017013 (posted April 3, 2026) exploring vendor capabilities for direct-to-manufacturer prescription programs. The mismatch between the code's name and actual recent solicitations suggests this commodity code sees limited direct procurement activity in the current market.